This research service examines the advancements in epifluidic diagnostics technology, identifying the growth opportunities they present for the healthcare industry. Epifluidic diagnostics is an emerging class of wearable diagnostics that enables sweat and interstitial fluid (ISF) analysis through skin-interfaced microfluidic systems. These body-worn skin-conformable and flexible miniature devices with microelectronics, sensors, and flexible microfluidics allow long-term, painless, and continuous sampling of the alternate biofluids and real-time and continuous monitoring of diagnostic targets for precise health management. Technology advancements in this field, particularly the integration of artificial intelligence (AI) and machine learning (ML) solutions, help enable higher diagnostics accuracy and enhanced user convenience. Researchers have found evidence that sweat- and ISF-based diagnostics can be used for a diverse range of applications, including viral infection detection, cystic fibrosis diagnosis, urea monitoring, and Parkinson's disease management. Sweat-based epifluidic diagnostics are predominantly utilized for hydration management and substance-use detection, while ISF-based epifluidic diagnostics are employed for metabolite measurement. Key players are actively expanding ISF-based epifluidic diagnostics for more clinical uses, such as therapeutic drug monitoring, cardiovascular disease monitoring, and sepsis detection. With several sectors of impact, epifluidic diagnostics has high market potential in the coming years. The report takes a comprehensive look at the different types of epifluidic diagnostic technologies and their benefits and identifies the factors driving and restraining the growth of this market. It also identifies the key participants in the sweat-based epifluidic diagnostics and ISF-based epifluidic diagnostics segments, examining the technologies they employ, their target applications, and commercial readiness levels. The study covers regional and industry trends, including funding rounds, mergers and acquisitions (M&A), and patents filed. The base year is 2022, and the forecast period is 2023 to 2027.--BEGIN PROMO--

Conventional diagnostics are performed in centralized laboratories involving painful sample collection, time-consuming and expensive logistics and long turnaround. Furthermore, due to the delay in the turnaround, the results indicate the health status of an individual several hours ago. 
Epifluidic diagnostics is an emerging class of wearable diagnostics that enable sweat or interstitial fluid analysis through skin-interfaced microfluidic systems. These body-worn skin-conformable and flexible miniature devices allow painless and continuous sampling of the alternate biofluids for long term and enables real-time and continuous monitoring of diagnostic targets for precise health management.
Sweat-based epifluidic diagnostics are predominantly utilized for hydration management and substance use detection, and interstitial fluid-epifluidic diagnostics are employed for metabolite measurement. Key players are actively expanding interstitial fluid-based epifluidic diagnostics for more clinical uses, such as therapeutic drug monitoring, cardiovascular disease monitoring and sepsis detection. Competitors are competing to provide critical applications, real-time insights, higher accuracy and enhanced user convenience.
Academic research groups have found evidences that sweat and interstitial fluid-based diagnostics can be used for a multitude of diverse applications, ranging from viral infection detection, cystic fibrosis diagnosis, urea monitoring to Parkinson's disease management. Therefore, with several sectors of impact, epifluidic diagnostics has a high market potential in the coming years.
Key players are integrating epifluidic diagnostic devices with advanced information and communication technologies, such as AI/ML algorithms. Therefore, it provides a growth opportunity for AI developers. The continuous health data from epifluidic diagnostic devices will also be valuable for digital twin technology developers.
The epifluidic diagnostic technologies, the benefits and their segments are detailed in the report. The drivers and restraints for the growth of the epifluidic diagnostics industry are explored. The participants in the sweat-based epifluidic diagnostics and interstitial fluid-based epifluidic diagnostics segments, the technologies they employ, their target applications and commercial readiness levels are discussed. The new applications emerging from the academic ecosystem have been explored in the report. The regional trends and development status of the epifluidic diagnostics segments for various applications, the funding, mergers and acquisitions (M&A) and the patent filing trend in the epifluidic diagnostics industry have been analyzed in detail. The growth opportunities for the epifluidic diagnostics industry have also been identified.